References
1. Arakelyan M.G., Bockeria L.A., Vasil’eva E. Yu., Golitsyn S.P., Golukhova E.Z., Gorev M.V., et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2021; 26 (7): 190–260. DOI: https://doi.org/10.15829/1560-4071-2021-4594 (in Russian)
2. Schnabel R.B., Yin X., Gona P., Larson M.G., Beiser A.S., McManus D.D., et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015; 386 (9989): 154–62. DOI: https://doi.org/10.1016/s0140-6736(14)61774-8
3. Kornej J., Börschel C.S., Benjamin E.J., Schnabel R.B. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020; 127 (1): 4–20. DOI: https://doi.org/10.1161/circresaha.120.316340
4. Chugh S.S., Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E.J., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129 (8): 837–47. DOI: https://doi.org/10.1161/circulationaha.113.005119
5. Mareev Yu.V., Polyakov D.S., Vinogradova N.G., Fomin I.V., Mareev V. Yu., Belenkov Yu.N., et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF study. Kardiologiya [Cardiology]. 2022; 62 (4): 12–9. DOI: https://doi.org/10.18087/cardio.2022.4.n1997 (in Russian)
6. Luk’yanov M.M., Andreenko E. Yu., Martsevich S. Yu., Yakushin S.S., Vorob’ev A.N., Pereverzeva K.G., et al. Patients with atrial fibrillation in clinical practice: comorbidity, drug treatment and outcomes (data from RECVASA registries). Ratsional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2020; 16 (6): 888–98. DOI: https://doi.org/10.20996/1819-6446-2020-12-01 (in Russian)
7. Ionin V.A., Barashkova E.I., Filatova A.G., Baranova E.I., Shlyakhto E.V. Atrial fibrillation in St Petersburg cohort: frequency, risk factors, antiarrhythmic therapy and thromboembolism prevention. Arterial’naya gipertenziya [Arterial Hypertension]. 2020; 26 (2): 192–201. DOI: https://doi.org/10.18705/1607-419x-2020-26-2-192-201 (in Russian)
8. Yakusevich V.V., Yakusevich V.V., Martsevich S. Yu., Luk’yanov M.M., Drapkina O.M. Patients with atrial fibrillation in outpatient practice: clinical characteristics and outcomes over a 10-year observation period (data from the REQUAZA AF registrу – Yaroslavl). Ratsional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2023; 19 (5): 486–94. DOI: https://doi.org/10.20996/1819-6446-2023-2945 (in Russian)
9. Kasimova A.P., Tufanova O.S., Kolbin A.S. Socio-economic burden of atrial fibrillation in the Russian Federation: dynamics over 12 years. Kachestvennaya klinicheskaya praktika [Qualitative Clinical Practice]. 2023; (2): 53–8. (in Russian)
10. Shlyakhto E.V., Baranova E.I. Central directions for reducing cardiovascular mortality: what can be changed today? Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2020; 25 (7): 10–8. DOI: https://doi.org/10.15829/1560-4071-2020-3983 (in Russian)
11. Gorbunova E.V., Duvanova S.P., Mamchur S.E. Atrial fibrillation in real clinical practice at the outpatient stage. Vestnik aritmologii [Bulletin of Arrhythmology]. 2023; 30 (1): 5–10. DOI: https://doi.org/10.35336/VA-2023-1-01 (in Russian)
12. Shapkina M. Yu., Mazdorova E.V., Avdeeva E.M., Shcherbakova L.V., Ryabikov A.N., et al. Changes in the prevalence of atrial fibrillation in the Russian population over a 13-year follow-up. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2022; 21 (8): 23–33. DOI: https://doi.org/10.15829/1728-8800-2022-3108 (in Russian)
13. Valiakhmetov M.N., Gomova T.A., Luk’yanov M.M., Martsevich S.Y., Nadezhkina K.N., Artemova M.N., et al. Patients with atrial fibrillation in multidisciplinary hospital: structure of hospitalization, concomitant cardiovascular diseases and drug treatment (data of RECVASA AF-Tula registry). Ratsional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2017; 13 (4): 495–505. DOI: https://doi.org/10.20996/1819-6446-2017-13-4-495-505 (in Russian)
14. Proietti M., Romiti G.F., Vitolo M., Harrison S.L., Lane D.A., Fauchier L., et al. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing. 2022; 51 (8): afac192. DOI: https://doi.org/10.1093/ageing/afac192
15. Alonso A., Krijthe B.P., Aspelund T., Stepas K.A., Pencina M.J., Moser C.B., et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF Consortium. J Am Heart Assoc. 2013; 2 (2): e000102. DOI: https://doi.org/10.1161/jaha.112.000102
16. Sanoski C.A. Prevalence, pathogenesis, and impact of atrial fibrillation. Am J Health Syst Pharm. 2010; 67 (9 suppl 5): 11–6. DOI: https://doi.org/10.2146/ajhp100148